Premature ovarian failure occurs in almost 1% of women under age 40. Molecular alterations of the FSH receptor (FSHR) have recently been described. A first homozygous mutation of the FSHR was identified in Finland. More recently, we described two new mutations of the FSHR in a woman presenting a partial FSH-resistance syndrome (patient 1). We now report new molecular alterations of the FSHR in another woman (patient 2) who presented at the age of 19 with primary amenorrhea contrasting with normal pubertal development. She had high plasma FSH, and numerous ovarian follicles up to 3 mm in size were evidenced by ultrasonography. Histological and immunohistochemical examination of ovarian biopsies revealed the presence of a normal follicular development up to the antral stage and disruption at further stages. DNA sequencing showed two heterozygous mutations: Asp224Val in the extracellular domain and Leu601Val in the third extracellular loop of FSHR. Cells transfected with expression vectors encoding the wild type or the mutated Leu601Val receptors bound hormone with similar affinity, whereas binding was barely detectable with the Asp224Val mutant. Confocal microscopy showed the latter to have an impaired targeting to the cell membrane. This was confirmed by its accumulation as a mannose-rich precursor. Adenylate cyclase stimulation by FSH of the Leu601Val mutant receptor showed a 12 ؎ 3% residual activity, whereas in patient 1 a 24 ؎ 4% residual activity was detected for the Arg573Cys mutant receptor. These results are in keeping with the fact that estradiol and inhibin B levels were higher in patient 1 and that stimulation with recombinant FSH did not increase follicular size, estradiol, or inhibin B levels in patient 2 in contrast to what was observed for patient 1. Thus, differences in
INTRODUCTION
Normal pubertal development and fertility depend on the interplay of hypothalamic, pituitary, and gonadal factors. Various genetic defects of the hypothalamicpituitary-gonadal axis that cause hypogonadism have been identified (reviews in Refs. 1 and 2). FSH and its receptor play a pivotal role in follicular development and in female fertility. This receptor belongs to a highly homologous subgroup of G protein-coupled receptors that also includes the LH and TSH receptors (review in Ref. 2) . The recent description of mutations of the FSH receptor has provided insights into the role of FSH at different steps of follicular maturation.
The first mutation that was identified was the Ala189Val homozygous substitution detected in a highly consanguinous Finnish population (3) . It was associated with primary amenorrhea, streak ovaries containing primordial and primary follicles but without any further follicular development (4) . This observation indicated that the initiation of folliculogenesis was independent of FSH action. A similar conclusion has been very recently reached in mice with targeted disruption of the FSH receptor gene and which present a block in folliculogenesis at the preantral stage (5) . On the other hand, it is well known that FSH is necessary for the development of preovulatory follicules (6, 7) . Between these stages, the role of FSH for preantral or early antral follicles is still under discussion due to the lack of appropriate experimental models.
Recently we have described a novel phenotype associated with partial loss-of-function mutations of the FSH receptor (8) . In this case the patient had primosecondary amenorrhea, high gonadotropin levels (especially FSH), and normal sized ovaries. Ultrasonography, ovarian histology, and immunocytochemistry showed a normal follicular development up to a small antral stage (follicles of 5 mm) and then a disruption at further stages. We now report a second such case associated with two different mutations. The patient presented primary amenorrhea and her antral follicles developed only to a size of 3 mm. She was a compound heterozygote bearing an Asp224Val or a Leu601Val mutation on each allele. As reported in the previous patient, transfection studies showed altered but not suppressed function of the mutated receptors. However the residual function was more limited than in the previous case. There was thus a correlation between receptor activity measured in vitro and the in vivo findings, i.e. the phenotype and the most advanced stage to which follicular development could proceed.
The propositus was a 19 yr-old Caucasian woman who consulted for primary amenorrhea. Puberty had occurred at the age of 13, with normal development of secondary sex characteristics. The patient was the second daughter of two nonconsanguinous parents. Her 21-yr-old sister described menstrual irregularity since her first menstruations at age 14. The patient's height was 174 cm and her weight 73 kg. Plasma FSH and LH were high, 63 and 26 IU/liter, respectively [normal (N): [4] [5] [6] [7] [8] . Plasma E 2 levels were low: 40-80 pmol/liter (N: 70-1000), and testosterone plasma level was 1.7 nmol/liter (N: 0.7-2.1 nmol/ liter), ⌬4-androstenedione was 8.4 nmol/liter (N: Ͻ5 nmol/liter) and dehydroepiandrosterone was 48.1 nmol/liter (N: 7-40 nmol/liter). Sex hormone binding globulin was at a normal low level: 34 nmol/liter (N: 30-69 nmol/liter). Plasma concentration of inhibin B was low, 30 pg/ml (N: 60-175 pg/ml). No antithyroid or antiovary autoantibody could be detected. The karyotype was normal: 46,XX. Pelvic ultrasonography showed a normal uterus and normal sized ovaries. Ten to 12 follicles of 3 mm were detected, regularly spread in each ovary. Under coelioscopy, two biopsies were performed on each ovary. The patient received an oral estrogen-progestin treatment (ethinyl-estradiol, 50 g, and norgestrel, 500 g) for 3 months. At the end of this treatment, plasma LH and FSH were low (1 IU/liter). An ovarian stimulation by recombinant FSH (Puregon, Organon, Puteaux, France) was performed with doses increased every 3-4 days until a cumulative dose of 5625 IU had been obtained. It was monitored by hormone assays and pelvic ultrasonographies.
The study was approved by the review boards of the different institutions. Informed consent was obtained from the patient and her family.
RESULTS

Sequencing of the FSH Receptor (FSHR) Gene
The sequencing of the complete coding region of the human FSHR gene in the patient revealed two heterozygous substitutions ( Fig. 1) : a substitution of an adenine for a thymidine in exon 9 yielded an Asp224Val substitution in the extracellular domain of the receptor. The second substitution of a cytosine for a guanine in exon 10 yielded a Leu601Val substitution in the third extracellular loop of the receptor. Each parent of the propositus was heterozygous for one of the mutations. The father carried the Asp224Val and the mother the Leu601Val substitution. The sister was heterozygous for the Leu601Val mutated allele.
Functional Study of the Mutated Receptors
Cells transfected with either the wild-type or the mutated Leu601Val receptors bound FSH with a similar affinity ( Fig. 2A) . By contrast, FSH binding to the Asp224Val receptor was barely detectable.
FSH-induced adenylate cyclase stimulation was then studied in COS-7 cells transfected with expression vectors encoding the wild-type or the mutated receptors (Fig. 2B) . The Leu601Val mutant did not cause stimulation of adenylate cyclase at low FSH concentrations. However, for very high FSH concentrations, a limited accumulation of cAMP was observed. There was no hormone-induced synthesis of cAMP in cells expressing the Asp224Val mutant receptor. Three experiments were performed with similar results. Circles correspond to the wild type, squares to the Asp224Val, and triangles to the Leu601Val FSHR mutants.
Fig. 1. Pedigree of the Family (A) and Location (B) of the two Mutations Detected in the Patient
In panel A, the propositus is indicated by an arrow. Solid symbols denote affected subjects, half-solid symbols denote unaffected heterozygotes, circles indicate females and squares indicate males. In panel B, the two heterozygotic mutations are indicated in the extracellular domain and in the third extracellular loop of the FSHR.
Altered Surface Targeting and Processing of the Asp224Val Receptor Mutant
Impaired FSH binding to cells expressing the Asp224Val mutant receptor could have been due either to a modification of the binding site or to an alteration in receptor cellular trafficking. To distinguish between these two possibilities, cells were transfected with the wild-type or the mutated receptors, and receptor distribution was studied (Fig. 3) . Transfected cells were incubated with an antibody directed against the extracellular domain of the receptor. When the cells were permeabilized with saponin before the incubation with the antibody, a strong intracellular staining was observed in all cases. When the cells were not permeabilized, labeling was observed on the cell surface for cells expressing the wild-type receptor or the Leu601Val mutant, but no labeling was observed for cells expressing the Asp224Val mutant receptor.
In experimental mutagenesis studies, intracellular trapping of mutated receptors has often been observed to be associated with an altered processing of the glycoprotein (9) . We thus studied the glycosylation of the Asp224Val mutant receptor as compared with the wild-type receptor. For that purpose, the receptor was immunopurified from transfected cells and submitted to deglycosylation by endoglycosidase H (specific for high-mannose precursor moïeties of glycoproteins) or N-glycanase F (which removes all N-linked glycosaccharides). Receptors were analyzed by Western blot using a monoclonal antireceptor antibody.
As shown in Fig. 4 , two species corresponding to the wild-type receptor were detected as previously described (10) . The highest molecular mass species of approximately 87 kDa was resistant to endoglycosidase H but sensitive to N-glycanase F and resolved into an approximately 75 kDa species. It corresponds to the mature receptor, which has undergone a complete glycosylation and which is expressed at the cell surface (10) . The approximately 81 kDa species was sensitive to both N-glycanase F and endoglycosidase H and resolved into an approximately 75 kDa species. It thus corresponds to a protein with high-mannose moïeties, which has been shown to be a precursor of the FSHR (10) . Such a precursor accumulates in the endoplasmic reticulum (11) .
In cells expressing the Asp224Val mutant, only the precursor was observed, and no mature receptor carrying complex carbohydrates could be detected (Fig. 4B ).
Histological and Immunohistochemical Studies of the Ovary
Histological examination of ovarian biopsies showed a normal number of healthy primordial and primary follicles (Fig. 5A ). Secondary follicles also displayed a normal morphology (Fig. 5B) . Three antral follicles were found in the biopsies: the two smaller (0.22 and 0.28 mm) were apparently normal (not shown), whereas the larger (diameter: 0.8-1 mm) was clearly degenerating (Fig. 5C ). It had an irregular antrum containing remnants of granulosa cell layers. The basal lamina was thick and irregular and the theca interna was hypertrophied (100-150 m).
Immunocytochemical studies were undertaken on this follicle. They showed a strong staining of thecal cells for side chain cleavage enzyme (P450 scc ) (not shown) and for 17␣ hydroxylase (P450 c17 ) (Fig. 5D) . The theca was also stained for 3␤-hydroxysteroid dehydrogenase, but the labeling was markedly weaker ( Fig. 5E ) and thus contrasted with that observed in the previously studied patient 1 (7) . No immunostaining could be observed with the antiaromatase antibody (not shown).
Correlation of Receptor Function with Clinical and Biological Findings in Patients with Partial Ovarian Failure and FSHR Mutations
We have previously reported another patient (patient 1) bearing two heterozygous mutations of the FSHR gene (8) . We compared the activity of her transfected receptors with that of the present case (patient 2). We then related these observations to the effects of FSH in vivo in the two patients.
The biological activity of the four mutated FSHRs was compared with that of the wild-type receptor (Fig.  6 ). Similar transfection efficiencies were assessed using a ␤-galactosidase assay. This experiment was reproduced four times with similar results. The mutations yielded receptors with residual activities of 24 Ϯ 4% for the Arg573Asp (patient 1) and 12 Ϯ 3% for the Leu601Val (patient 2) receptor mutants, respectively, after a maximal stimulation by FSH. Activities of the mutated receptors Ile160Thr (patient 1) and Asp224Val (patient 2) were more severely altered, 9 Ϯ 2% and 4 Ϯ 2% of the wild-type receptor, respectively. Residual activity was therefore higher in the receptor mutants carried by patient 1 as compared with patient 2. This could be related to the fact that patient 1 had antral follicles developing up to 5 mm whereas patient 2 had follicles developing only to 3 mm at ultrasonography. Furthermore, plasma estradiol and inhibin B levels were 70-150 pmol/liter and 50 pg/ml in patient 1 and 40-80 pmol/liter and 30 pg/ml in patient 2. Patient 2, therefore, showed a lower sensitivity to endogenous FSH than patient 1 ( Table 1) .
The difference was even more marked when exogenous FSH was administrated in vivo to both patients. Recombinant FSH was injected in increasing doses to a final total dose of 5625 U. In Patient 1, this stimulation increased the follicular size up to 8.3 mm, whereas no change in follicular size was observed in patient 2. Plasma estradiol and inhibin B levels also markedly increased from 35 to 240 pmol/liter and from 50 to 125 pg/ml, respectively, in patient 1, whereas no significant change was observed in patient 2 under stimulation with the same increasing doses of recombinant FSH (Table 1 ). For ethical reasons it was decided not to further increase the dose of FSH.
There was thus a correlation between the FSH-stimulated in vitro activity of the mutated receptors found in the two patients and their in vivo response to endogenous and exogenous FSH.
DISCUSSION
We report here two novel mutations of the FSHR gene in a woman (patient 2) presenting with primary amenorrhea, low ovarian estrogen secretion, and follicular growth up to the early antral stage with a maximal diameter of 3 mm at ultrasonography. This patient was a compound heterozygote, having inherited a different mutated allele from each parent: Asp224Val in exon 3 from her father and Leu601Val in exon 10 from her mother. This is the second patient observed presenting with premature ovarian failure (POF) due to partial loss of function mutations of the FSHR gene.
POF concerns almost 1% of women under age 40 (12) . It has long been suspected that POF could be due, in some cases, to an ovarian resistance to gonadotropin stimulation, since a few patients with amenorrhea but also presence of follicles at ovarian histology have been reported (13) . This FSH resistance ovary syndrome is better understood now that inactivating mutations of the FSHR gene have been described. A first homozygous mutation (Ala189Val) was identified in a Finnish population of ovarian dysgenesis (3), with primary amenorrhea and delayed puberty in most cases (4) . Histological study of the ovaries in some of these patients showed a streak or hypoplastic aspect and the presence of primordial and primary follicles with impaired follicular development at further stages. The mutation dramatically impaired receptor function. This mutation has not been detected in patients outside of Finland who display the same phenotype (1, 8, 14) . More recently, we reported the case of a patient (patient 1) who was a compound heterozygote for two inactivating mutations of the FSHR (8) . The phenotype of this patient was different from the one described in the Finnish population. Indeed, patient 1 presented with secondary amenorrhea, normal sized ovaries including antral follicles up to 5 mm. The mutations impaired, but did not abolish, FSHR function. By analogy with the molecular defects found in the related LH or TSH receptors (reviews in Refs. 2 and 15), we postulated that such partial cases may be more frequently observed than complete loss of FSHR function. Indeed, patient 2 was also found to have partial impairment of FSHR function. Clinically, this patient had a more severe phenotype with primary amenorrhea. She had smaller follicles than those of patient 1 at ultrasonography and a complete absence of response to recombinant FSH at a total dose of 5625 IU, which elicited in patient 1 a progressive increase in follicular growth (from 5 to 8.3 mm), and plasma concentrations of estradiol (from 35 to 240 pmol/liter) and inhibin B (from 50 to 125 pg/ml).
Functional analysis of the mutated receptors revealed a correlation with the phenotypes observed. Indeed, in the Finnish report, the homozygous extracellular mutation of the FSHR yielded a receptor with no significant response to hormone in vitro (3). Patient 1 was a compound heterozygote; one of the two mutations, the Arg573Cys mutation, yielded a receptor with a residual 24 Ϯ 4% activity when compared with the wild-type receptor. In the case of patient 2, one of the two mutant receptors, the Leu601Val mutant, had 12 Ϯ 3% residual activity when compared with the wild-type receptor. In both patients the other mutant receptors were almost completely inactive.
Interestingly, in both patients 1 and 2, follicular development occurred up to the antral stage, but ultra- sonographic examination showed that it proceeded up to a follicular size of 5 mm in patient 1 and only 3 mm in patient 2. The fact that FSH stimulation was able to increase follicular size as well as estradiol, and inhibin B secretion in patient 1 indicated that ovarian follicles of this patient were partly responsive to high concentrations of FSH. In Patient 2, the same maximal dose of recombinant FSH was ineffective, and this can be explained by a more pronounced alteration of receptor function associated with a less important initial follicular development.
FSH effects on follicular growth and maturation differ markedly at various developmental stages. A body of evidence indicates that in mice and rats initiation of follicular growth, when a resting follicle enters the growth phase, does not require FSH (16, 17) . The absence of FSHR gene expression in nongrowing human follicles confirms this point (18) . Evidence points to the need of FSH for further follicular development between the primary and the antral stage. In rat models, hypophysectomy or GnRH antagonist administration leads to an almost complete absence of follicular growth beyond the secondary stage (19) . The same pattern has been obtained in xenografts of human ovarian tissues in hypogonadal SCID/hpg mice, (20) . Finally, in mice bearing a homozygous invalidation of either the FSH␤ (21) or the FSHR (5) gene, development was blocked before the antral stage. In humans, clinical observations also suggest FSH independence during the first steps of follicular development. In situations where low levels of circulating gonadotropins are present, i.e. prepubertally or in women with hypogonadotropic hypogonadism or with mutations of FSH␤, morphological examination of the ovaries revealed the existence of small preantral follicles but few antral follicles, indicating that gonadotropin deficiency is associated mainly with a disruption of the final stages of preovulatory folliculogenesis (6, (22) (23) (24) (25) .
The arrest of follicular development at a relatively precise stage in each of our two patients suggests that a different FSH or receptor activity is necessary to promote the maturation of antral follicles in each case. Growth may be arrested at various stages depending on how severely FSHR function is impaired.
A different mechanism has been proposed in preovulatory follicles. A threshold concentration of FSH must be reached. But once started, the final follicular development proceeds up to the ultimate stages, even if the concentration of FSH decreases (7, 26) .
Immunohistochemical studies of the ovaries of patient 2 revealed only a faint staining for 3␤-hydroxysteroid dehydrogenase (3␤-HSD). This observation is also in agreement with a more pronounced defect in follicular development than in patient 1, in whom theca cells were found to express this enzyme. It has been shown during preovulatory follicle maturation in pigs that maximal expression of theca 3␤-HSD was observed only 4 days after maximal expression of P450 aromatase and P450c17 (27) . This led to the proposal that 3␤-HSD is rate limiting for the overall follicular steroidogenesis by limiting the substrate for P450c17.
The cellular expression of the mutated receptors highlights the crucial role of two residues in FSHR function. The Asp224Val mutation (patient 2) yielded a receptor that was not expressed at the cell membrane. A similar situation was found for the Ile160Thr receptor mutant (patient 1). The study of the glycosylation of the mutated receptors indicates that they carry mannoserich carbohydrates and have thus not reached the Golgi apparatus. This impairment of receptor cell trafficking may be due to an altered receptor conformation, which impedes the further progression of the receptor in other cellular compartments. The accumulation of misfolded proteins triggers the ER unfolded response inducing the selective synthesis of endoplasmic reticulum chaperones that bind to misfolded exportable proteins (28) (29) (30) . This accumulation, alternatively, may be due to the lack of interaction of the mutated receptor with a specific chaperone necessary for proper receptor folding (31) .
The Leu601Val substitution was characterized by an impairment in signal transduction, without any change in its affinity for FSH. It thus highlights the role of the third extracellular loop in FSHR transduction. However, mutation of the same leucine 601 [numbered Leu583 by Ryu et al. (32) ] into an alanine improved hormone binding affinity by 4-to 6-fold, indicating an inverse relationship with cAMP stimulation. This observation led to the suggestion that leucine 601 interacted with the ectodomain and constrained hormone binding in the wild-type receptor (32) . We could not confirm this hypothesis since repeated experiments in our study failed to detect a significant difference in FSH binding affinities of the wild-type and of the mutated receptor. Leucine 601 may thus be involved in maintaining the proper conformation of exoloop 3 and of the adjacent transmembrane helices 6 and 7. The latter have been shown to be important in signal transduction (33) .
In conclusion, novel mutations of the FSHR have been identified that lead to a novel clinical phenotype. There was a correlation between the residual activity of the mutated receptors and the phenotype. These new observations offer a model to understand the role of FSH during the early steps of follicular development.
MATERIALS AND METHODS
DNA Sequencing
DNA was extracted from peripheral blood leukocytes. The 10 exons of the human FSHR gene were amplified by PCR and sequenced on both strands using previously described primers (3, 34) . Genomic sequencing was performed using a Taq dideoxyterminator cycle sequencing kit and a 373 A automated sequencer (PE Applied Biosystems, Foster City, CA).
Construction of Expression Vectors Encoding Mutated FSHRs
The human FSHR cDNA cloned into the pSG5 expression vector has been described elsewhere (8) . The mutations were introduced into the pSG5-FSHR plasmid vector by oligonucleotide-mediated mutagenesis using PCR.
The Leu601Val substitution was engineered with two mutagenic primers: a direct primer A1: 5Ј-AGGTGCCCGTCAT-CACTGTGTCCAA-3Ј and a reverse primer B1: 5Ј-CACAGT-GATGACGGGCACCTTGAGG-3Ј starting, respectively, at positions 1793 and 1813 of the cDNA sequence (ϩ1 corresponds to the first nucleotide of the initiation codon) (35) . The mutated base is underlined.
Two other primers were used. Primer C1: GCTGCTCATT-GCATCAGTTGATATCCATAC; and primer D1: GAGGGA-CAAGTATGTAAGTGGAACCACTGG, starting at positions 1245 and 2036, respectively, of the cDNA sequence. A fragment of 821 bp containing the mutation was constructed in two pieces. The first fragment was obtained by PCR using oligonucleotides A1 and D1. The second fragment was obtained using oligonucleotides B1 and C1. The full-length product of 821 bp was obtained by hybridization of the two fragments and PCR amplification using primers C1 and D1. After digestion with PfIMI (there are two PfIMI sites located at distances of 413 and 298 bp on either side of the mutation), the fragment was ligated into the pSG5-hFSHR vector, which had been previously digested with PfIMI. The Asp224Val substitution was generated using a similar strategy. Two mutagenic primers were used: a direct primer A2 (5Ј-GTCAT-TCTAGTTATTTCAAGAACAAGGATC-3Ј) and a reverse primer B2 (5Ј-CCTTGTTCTTGAAATAACTAGAATGACTGG-3Ј) starting at position 467 and 492 of the cDNA sequence, respectively (the mutated base is underlined). The two other primers were C2 (GGACCTGGAGAAAATAGAGATCTCTC-AGAA) and D2 (GACCCCTAGCCTGAGTCATATAAT-CAACTT) and started at positions 210 and 929 of the cDNA sequence, respectively.
The full-length fragment of 719 bp containing the Asp224Val mutation was digested with AflII and Bsu36 I (the restriction sites were located 141 bp upstream and 242 bp, respectively, downstream from the mutation), purified, and ligated to the pSG5-FSHR vector digested with the same restriction enzymes.
All constructs were verified by double-strand sequencing.
Study of FSH Binding to the Wild-Type and Mutated Receptors
COS-7 cells were transfected with the wild-type and the mutated receptors using Superfect (Qiagen, Chatsworth, CA) as previously described (8) . Forty-eight hours later, cells were incubated for 1 h at 30 C with 400,000 cpm/ml of radioiodinated FSH (Amersham Pharmacia Biotech, Arlington Heights, IL; specific activity, 135 Ci/g) as previously described (8) .
The incubations were performed in the absence or in the presence of increasing concentrations of unlabeled recombinant FSH. Nonspecific binding was determined in samples containing an excess (10 g/ml) of unlabeled FSH and subtracted from the total binding. All experiments were performed twice with triplicate samples. Transfection efficiencies were estimated by cotransfecting pRSV-␤gal and measuring ␤-galactosidase activity in the cells. Similar efficiencies were observed when expression vectors encoding either the wild-type or the mutated FSHRs were used.
cAMP Assay cAMP was measured as previously described (8) 
Immunofluorescence and Confocal Microscopy
Indirect immunofluorescence studies were performed on COS-7 cells transiently expressing wild-type or mutated FSHR using the monoclonal FSHR 323 antibody (8) . This antibody, which recognizes an epitope located in the extracellular domain of the FSHR (10), allows the study of receptor expression at the cell membrane. For this purpose, intact cells or permeabilized cells were incubated with the antibody as previously described (8) . A Cy3-labeled rabbit antimouse IgG (Sigma Chemical Co., St Louis, MO) was used as a secondary antibody. Immunofluorescence was then analyzed with an Axiovert 135M microscope (Carl Zeiss, Thornwood, NY) in conjunction with a confocal LSM 410 laser scanning unit (Carl Zeiss) (8, 36) .
Immunoblotting of FSHR
COS-7 cells were transfected as described above. They were scraped 48 h later in PBS containing protease inhibitors. After centrifugation at 800 ϫ g for 10 min at 4 C, the pellet of cells was suspended in solubilization buffer as previously described (10). The receptor was then immunopurified from membrane extracts using the FSHR323 antibody coupled to Affi-Gel 10. The purified FSHR was quantified using a specific immunoenzymatic assay (10) . The receptor (300 fmol) was then deglycosylated with N-glycanase F or endoglycosidase H as previously described (10, 37) . The immunopurified human (h) FSHR was electrophoresed on a 8% SDS polycrylamide gel under reducing and denaturing conditions. Proteins were electrotransferred to nitrocellulose and detected using the FSHR323 antibody as previously described (10, 37) .
Histological and Immunohistochemical Study
The ovarian biopsy from patient 2 was fixed in buffered formol and embedded in paraffin. Some sections were stained with conventional histological stains (hematoxylineosin, Masson's trichrome) for optical microscopy while the other sections were processed for immunohistochemistry.
The expression of steroidogenic enzymes was studied on paraffin sections after deparaffinization and antigen retrieval in 0.01 M citrate buffer, pH 6, in a 800 W microwave oven at full power for three cycles of 5 min as described (38) .
The following polyclonal rabbit antibodies were used: anti-P450-side chain cleavage enzyme (P450 scc ) (39) (dilution 1:3000), anti-3␤-HSD (40) (dilution 1:3000), anti-17␣ hydroxylase (P450 c17␣ ) (41) (dilution 1:5000), and antiaromatase (P450 arom ) (42) (Hauptman-Woodward Medical Research Institute, Inc., Buffalo, NY) (dilution 1:3000). They were incubated overnight with the sections at 4 C in a humid chamber. Endogenous peroxidase was quenched with 3% H 2 O 2 in PBS (pH 7.4) for 5 min. The bound Igs were revealed with an antirabbit biotinylated antibody and with peroxidase-labeled streptavidin (LSAB2 immunostaining kit, DAKO Corp., Carpinteria, CA) used according to manufacturer's instructions. Aminoethylcarbazole (Sigma Chemical Co.) was used as a chromogen and Meyer's hematoxylin was used as a nuclear counterstain. Replacement of the primary antibody with preimmune rabbit Igs at the appropriate dilution resulted in the absence of immunolabeling. Polyclonal anti-Von Willebrandt factor antibody (DAKO Corp.) was used to define thecal vascularization.
